Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSP304 Dose Ranging in Mild to Moderate COPD
NCT03118765Phase 2Completed
- Sponsor
- Glenmark Specialty
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tiotropium in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Glenmark Specialty. Primary endpoints: Relative Bioavailability of Tiotropium Based on CmaxSS at Day 21, Relative Bioavailability of Tiotropium Based on AUC0-tauSS at Day 21 and 1 more. Started Mar 2017; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03118765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118765.